DDAH1 and cancer: The most recent and comprehensive study which describes a role for DDAH1 pharmacological inhibition in cancer demonstrates the ability of the compound 3-amino-6-tert-butyl-N-(1,3-thiazol-2-yl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide (DD1E5) to irreversibly inhibit DDAH1 activity in prostate cancer cells (56).